AFM Portaal en AFM-website niet bereikbaar komend weekend
Vanaf vrijdag 4 oktober 21.00 uur tot zondag 6 oktober 21.00 uur is het AFM Portaal niet bereikbaar. Vanaf zaterdag 5 oktober 06.00 uur tot zondag 6 oktober 21.00 uur is de AFM-website niet bereikbaar.
argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
17 nov 2015 - 07:00
Statutaire naam
argenx SE
Titel
argenx Reports Third Quarter 2015 Financial Results and Provides Business Update
Bericht
Breda, the Netherlands / Ghent, Belgium, 17 November 2015 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided development program updates and announced financial results for the third quarter ended 30 September 2015.
"We continue to be very pleased with the progress being made here at argenx as we continue to advance our clinical pipeline of four novel antibody compounds in oncology and inflammation, including the first human dosing this quarter of ARGX-113, a potential breakthrough therapy for the treatment of autoimmune crisis. This pipeline, developed in only six years, is based on our highly productive SIMPLE AntibodyTM platform," commented Tim Van Hauwermeiren, chief executive officer of argenx. "With key strategic alliances from prominent industry partners, including Shire, LEO and Bayer, as well as our strong cash position, premier technology suite and growing pipeline we are well-positioned to develop a premier biotechnology company based on truly novel and value added drugs."
Datum laatste update: 06 oktober 2024